Stocks
Kailera Therapeutics, Inc.KLRA
NASDAQHealthcareBiotechnology$12.72
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its pipeline targets conditions such as obesity and diabetes, with a focus on next-generation treatments. Investors track Kailera for its potential to address large, growing markets in metabolic health.
52W Range: $9.76-$28.23
Congressional Interest in Kailera Therapeutics, Inc. (KLRA)
No congressional trades have been disclosed for Kailera Therapeutics, Inc. (KLRA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading KLRA?
No congressional trades found for this stock.